Objective: The research aims to prepare and characterize solid lipid nanoparticles (SLNPs) containing artemether. Method: The solvent diffusion approach was employed to produce artemether-loaded SLNPs. Artemether is one of the most widely used antimalarial medications, and it is the only one that can cure the relapsing form of malaria. Artemisinin has low water solubility, low bioavailability, and a short half-life, necessitating continual dose to maintain acceptable therapeutic drug-plasma concentration; therefore, we solve this issue by creating solid lipid nanoparticles. Nano formulation of pharmaceuticals in an appropriate drug carrier system has been extensively explored and found to have the potential to improve bioavailability, hence increasing activity, reducing dose frequency, and, as a result, lowering toxicity. Results: The produced SLNs had particle size, polydispersity index (PDI), and zeta potential (ZP) values ranging from 211.6 to 389.9 nm, 0.277 to 0.723, and -17.8 to -16.5 mV, respectively. SEM, XRD, PDI, Zeta potential, Entrapment efficacy, and percentage yield, as well as all other examinations, were completed successfully. The optimized F6 batch released medicine at a rate of 98.07%. Optimized batch involves research like Differential scanning calorimeter thermograms showed that the medication is more physically stable in manufactured formulations. Negligible changes in drug characteristic peaks in Fourier transform infrared spectra indicated that there was no interaction between the various components in the nanoparticle formulation. Conclusion: Solid lipid nanoparticles containing artemether were successfully developed. The improved F6 batch released 98.07% of the medication within 6 hours. The optimized batch was stored for stability testing.